ERBB2 and cancer: Successful clinical anti-cancer multi-target kinase inhibitors include: sunitinib against platelet-derived growth factor receptor (PDGFR) and VEGFR, dasatinib against Abl and Src, sorafenib against Braf and VEGFR, and lapatinib against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2 or ERBB2).